[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tremor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tremor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,78,124,152,181,204,218,234,259,284,307,333,358],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100471009","natural-history-protocol-for-movement-disorders-100471009",false,"NCT05413291","Natural History Protocol for Movement Disorders","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 2 and above\n* Either one of these:\n\n  * Have or suspected to have a diagnosis of a movement disorder.\n  * Family member of someone who has or is suspected of having a diagnosis of a movement disorder.\n* Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets the following criteria will be excluded from participation in this study:\n\n-Being \\\u003C 2 years old.",true,"ALL","2 Years","100 Years",{"count":20,"type":21},4000,"ESTIMATED","OBSERVATIONAL","Background:\n\nA movement disorder is a condition that causes a person s body to move in ways that are not normal. There are different types. Some disorders cause movements people can t control, such as tics or shaking. Some cause reduced or slow movements. Movement disorders can cause disability in people. Sometimes members of the same family will have the same disorder. Researchers want to learn more about how people develop these disorders. This research could lead to better treatments.\n\nObjective:\n\nThis natural history study will collect data on people with different types of movement disorders. It will also collect data on their family members. The data will support further research.\n\nEligibility:\n\nChildren and adults aged 2 years and older who have a movement disorder. Family members of people with movement disorders are also needed.\n\nDesign:\n\nParticipants will undergo screening. They will have a physical exam. Researchers will look at their existing medical images. Any photographs or videos of their movements will also be reviewed.\n\nMost participants will come to the NIH clinic for only 1 visit. They will answer questions about their condition. They will have normal tests used to diagnose their condition. They may have blood tests and different types of imaging scans. They may have tests to see how well their nerves function. The tests used will depend on the type of disorder they have.\n\nFamily members will have some of the same tests as people with disorders.\n\nParticipants will not receive any new treatments.\n\nSome participants may be asked to return for a follow-up visit.\n\nUp to 4000 people may participate.",[25,26,27],"Movement Disorder","Tremor","Parkinson's Disease",[25,26,27,29],"Natural History","RECRUITING","2026-06-24",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":34},"2022-10-17",{"date":38,"type":21},"2030-12-31",{"name":40,"class":41},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":42},"100592449","cerebellar-transcranial-alternating-current-stimulation-tacs-to-modulate-parkinsons-disease-tremor-100592449","NCT06993571","Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor","Closed-loop Phase-adaptive Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Activity in the Cerebello-thalamo-cortical Network to Reduce Parkinson's Disease Tremor","tACS_PD_TR","Inclusion Criteria:\n\n* Clinical diagnosis of Parkinson's disease based on UK Brain Bank criteria\n* Patient exhibiting moderate to severe hand tremor\n* Provision written informed consent by the patient\n\nExclusion Criteria:\n\n* History of other neurological disorders such as vascular malformations, ischemic or haemorrhagic stroke, cerebral neoplasia, epilepsy, or major psychiatric illness\n* Existence of heart pacemaker or metal implants in the body\n* Pregnancy","18 Years",{"count":53,"type":21},10,"INTERVENTIONAL",[56],"NA","Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by different motor symptoms, including tremor, which is particularly difficult to manage. Common treatments, such as dopaminergic therapy, can have limitations in efficacy. Recent advancements in non-invasive brain stimulation, specifically phase-adaptive transcranial alternating current stimulation (tACS), offer a promising approach to reduce PD tremor. In the current project, a newly developed closed-loop system delivers precisely synchronized cerebellar tACS by aligning stimulation with the intrinsic hand tremor signal. The study will assess the efficacy of this novel approach to reduce hand tremor in PD patients.",[59,26],"Parkinson's Disease (PD)",[61,62,63,64,65,66,67],"Parkinson's disease","Hand tremor","Transcranial alternating current stimulation","Non-invasive brain stimulation","Closed-loop stimulation","Phase-adaptive stimulation","Tremor entrainment","2026-04-28",{"date":70,"type":34},"2026-05-04",{"date":72,"type":34},"2025-04-16",{"date":74,"type":21},"2026-12-31",{"name":76,"class":77},"Universitätsklinikum Hamburg-Eppendorf","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":88,"conditions":89,"keywords":112,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100571728","neurosurgical-outcome-network-100571728","NCT06724029","Neurosurgical Outcome Network","Neurosurgical Outcome Network Per la Predizione Dell'Outcome in Neurochirurgia","NEON","Inclusion Criteria:\n\n* Neuro-oncological pathology: supratentorial and subtentorial tumors, intra and extra axial tumors excluding the skull base (anterior, middle and posterior fossa; sellar and parasellar region)\n* Basicranial pathology: tumors originating from the anterior cranial fossa, middle cranial fossa and posterior cranial fossa, sellar region with or without supratentorial\u002Fparasellar development.\n* Vascular pathology: aneurysms, AVMs, cavernomas, other pathologies (Moyamoya disease, dural fistulas, nontraumatic hematomas)\n* Traumatic pathology: diffuse damage (nonvisible diffuse damage, diffuse damage, diffuse damage with edema, diffuse damage with shift) and focal damage (acute\u002Fsubacute\u002Fchronic subdural hematoma, extradural hematoma, subarachnoid hemorrhage, intraparenchymal hematoma, fractures); hydrocephalus. The inclusion criterion for chronic subdural hematoma is recent bleeding for TBI with CT finding of chronic subdural hematoma candidate for evacuation surgery.\n* Spinal pathology: degenerative cervical (anterior\u002Fposterior), myelopathic, and trauma pathology; instrumented, uninstrumented thoracolumbar pathology (disc pathology, canal pathology), and trauma pathology; oncologic spinal pathology.\n* Functional pathology: Parkinson's disease, spasticity, trigeminal neuralgia, craniofacial pain\u002Falgia, neuropathic pain, tremor, dystonias, obsessive compulsive disorder, drug-resistant epilepsies, depression. Normotensive hydrocephalus.\n* Peripheral nervous system pathology: peripheral nerve compression syndromes, peripheral nerve and plexus tumors, brachial plexus and peripheral nerve trauma (contusion and section)\n* Malformative pathology: Chiari malformation type 1 and craniostenoses including both those framed in malformative syndromes and those not framed in malformative syndromes (monosutural craniostenoses: trigonocephaly, plagiocephaly, scaphocephaly; multisutural craniostenoses). Malformative hydrocephalus.\n* For cognitive and psychological assessment: age 18 years or older; adequate understanding of Italian language; diagnosis of glioma, meningioma, vascular pathology, spinal pathology\n\nExclusion Criteria:\n\n* For cognitive and psychological assessment: patients with psychiatric diseases in history and\u002For taking psychotropic drugs; presence of overt cognitive decline (not due to the injury) in history; patients younger than 18 years old.",{"count":87,"type":21},4500,"The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to assess outcomes and their predictors using measures agreed upon by the participating centers. Standardizing the evaluation of outcomes and predictors improves the quality of research, allows for data comparison, and facilitates a \"common language\" in routine clinical practice. Most importantly, it influences therapeutic decisions in various neurosurgical conditions. Clinically, the identified predictors can also be used during preoperative assessments to provide more precise guidance to patients undergoing surgery.",[90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,26,105,106,107,108,109,110,111],"Aneurysms","Arteriovenous Malformations","Cavernomas","Skull Base Tumors","Moyamoya Disease","Dural Fistulas","Subdural Hematoma","Extradural Hematoma","Subarachnoid Hemorrhage","Hydrocephalus","Parkinson&Amp;#39;s Disease","Spasticity","Trigeminal Neuralgia","Craniofacial Pain","Neuropathic Pain","Dystonias","Obsessive-compulsive Disorder","Drug-resistant Epilepsy","Depression","Normal Pressure Hydrocephalus","Tumors of Peripheral Nerves","Chiari Malformation Type 1",[113],"Neurosurgery Outcome Artificial Intelligence predictors","2026-03-25",{"date":116,"type":34},"2026-03-30",{"date":118,"type":34},"2022-12-05",{"date":120,"type":21},"2027-06",{"name":122,"class":77},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",27,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":151},"100368019","abbott-dbs-post-market-study-of-outcomes-for-indications-over-time-100368019","NCT04071847","Abbott DBS Post-Market Study of Outcomes for Indications Over Time","ADROIT","Inclusion Criteria:\n\n1. Subject is scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 180 days.\n2. Subject, or a legally acceptable representative, must provide written informed consent prior to any study-related procedure.\n\nExclusion Criteria:\n\n1. Subject is currently enrolled or plans to enroll in an investigational study that may confound the results of this study.\n2. Subject has anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results.\n3. Study center is located in the United States, and indication for DBS implant is not Parkinson's disease or disabling tremor.\n4. Study center is located in the United States, and the intended lead implant location is not at, or in close proximity to, the STN, GPi, or VIM thalamus.",{"count":132,"type":21},1000,"The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.",[135,136,137,26,138,139,140],"Movement Disorders","Parkinson Disease","Essential Tremor","Dystonia","Primary Dystonia","Secondary Dystonia","2026-01-07",{"date":143,"type":34},"2026-01-08",{"date":145,"type":34},"2019-11-26",{"date":147,"type":21},"2030-09",{"name":149,"class":150},"Abbott Medical Devices","INDUSTRY",48,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":54,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":42},"100614832","mrgfus-for-parkinsons-tremor-100614832","NCT07284719","MRgFUS for Parkinson's Tremor","Predictors and Mechanisms of Tremor Relapse After MR-Guided Focused Ultrasound Thalamotomy in Parkinson's Disease","Inclusion Criteria:\n\n* Established diagnosis of idiopathic Parkinson's disease\n* Tremor not manageable with optimal medication\n* Clinical Indication for MRgFUSth\n* Able to understand study requirements and provide consent\n* HOEHN and YAHR \\\u003C3\n\nExclusion Criteria:\n\n* Dementia or severe cognitive impairment\n* The presence of another significant neurological\u002Fpsychiatric disorder or significant disease\n* Severe psychopathology, not medically managed\n* Poor balance and gait function based on neurological examination\n* Epilepsy\n* Active drug abuse\n* History of stroke or structural lesions on MRI that could interfere with image analysis.\n* Contraindications for MRI\n* Cardiac pacemaker\n* Pregnancy or breast-feeding\n* Claustrophobia\n* Patients unable to lie on the back for 2-4 hours in the MR-scanner-setting\n* Patients who do not want information about findings of unknown disease during the trial\n* SDR (Skull density rate) lower than 0.35","50 Years","80 Years",{"count":162,"type":21},20,[56],"This study investigates magnetic resonance-guided focused ultrasound thalamotomy (MRgFUSth) for people with Parkinson's disease (PD) and tremor not responding to conventional standard doses of dopamine replacement therapy. The aim is to identify clinical and imaging biomarkers predictive of sustained tremor control up to 24 months after MRgFUSth treatment. Participants will undergo a suprathreshold levodopa test and ¹⁸F-DOPA PET imaging to evaluate dopaminergic and serotonergic involvement in tremor. All participants will receive MRgFUSth and be followed for 24 months with standardized clinical, cognitive, and quality-of-life assessments. The study seeks to improve understanding the possible mechanisms of tremor relapse and inform patient selection for MRgFUSth in PD.",[166,26],"Parkinson s Disease",[168,169,61,170,171,172],"MRgFUS","MR-guided focused ultrasound","tremor","Parkinson's tremor","Relapse","2026-01-05",{"date":141,"type":34},{"date":176,"type":34},"2025-12-01",{"date":178,"type":21},"2029-02",{"name":180,"class":77},"Aarhus University Hospital",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":15,"sex":16,"minAge":51,"maxAge":160,"enrollmentInfo":187,"targetDuration":4,"studyType":54,"phases":189,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":42},"100455915","early-phase-1-understanding-disorder-specific-neural-pathophysiology-in-laryngeal-dystonia-and-voice-tremor-100455915","NCT05216770","Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic background;\n2. Age 18-80 years;\n3. Native English speakers;\n4. Right-handed;\n5. Normal cognitive status;\n6. Patients will have laryngeal dystonia or voice tremor;\n7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent;\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;\n3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;\n4. Patients with any other form of dystonia;\n5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;\n6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;\n7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;\n8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;\n9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.",{"count":188,"type":21},165,[190],"EARLY_PHASE1","The researchers will examine functional neural correlates that differentiate between laryngeal dystonia and voice tremor and contribute to disorder-specific pathophysiology using a cross-disciplinary approach of multimodal brain imaging.",[193,194,26],"Laryngeal Dystonia","Spasmodic Dysphonia","2025-11-24",{"date":197,"type":34},"2025-12-02",{"date":199,"type":34},"2022-03-24",{"date":201,"type":21},"2027-08-31",{"name":203,"class":77},"Massachusetts Eye and Ear Infirmary",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":15,"sex":16,"minAge":51,"maxAge":160,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":42},"100450792","characterization-of-clinical-phenotypes-of-laryngeal-dystonia-and-voice-tremor-100450792","NCT05150106","Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic backgrounds;\n2. Age 18-80 years;\n3. Native English speakers;\n4. Right-handed;\n5. Normal cognitive status;\n6. Patients will have laryngeal dystonia or voice tremor;\n7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent;\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;\n3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;\n4. Patients with any other form of dystonia;\n5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;\n6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;\n7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;\n8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;\n9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.",{"count":188,"type":21},"The researchers will systematically evaluate current and novel clinical voice assessment tools and measures to elucidate distinct clinical phenotypes of those with laryngeal dystonia and voice tremor.",[193,194,26],{"date":197,"type":34},{"date":215,"type":34},"2022-11-07",{"date":201,"type":21},{"name":203,"class":77},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":160,"enrollmentInfo":224,"targetDuration":4,"studyType":54,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":233,"locationsCount":42},"100450791","deep-brain-stimulation-in-laryngeal-dystonia-and-voice-tremor-100450791","NCT05150093","Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor","Inclusion\n\n1. Clinical indications to proceed with DBS implantation, as determined by the clinical multidisciplinary movement disorders board, including: a) definitive diagnosis of essential tremor or dystonia, b) medically refractory disease, c) adequate performance on neuropsychological evaluation as determined by a licensed clinical neuropsychologist.\n2. The ability to comply with test directions, complete pre-operative task training, and provide informed consent.\n3. Age 18-80 years.\n\nExclusion\n\n1\\. Inability to understand or perform the task outlined in the protocol during a pre-surgery training session. 2. Significant hearing loss.\n\n3\\. Cortical venous anatomy that could potentially obstruct ECoG electrode placement, as determined by the surgeon, visualized on pre-op MRI or during surgery.",{"count":225,"type":21},120,[56],"The goals of this project are 1) to determine the incidence of neurological voice disorders in patients with dystonia and essential tremor undergoing deep brain stimulation (DBS), 2) investigate the neuroimaging and intracranial neurophysiology correlates of voice dysfunction in these subjects, and subsequently 3) determine the effects of DBS on voice function.",[193,194,26,138],{"date":197,"type":34},{"date":231,"type":34},"2022-06-21",{"date":201,"type":21},{"name":203,"class":77},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":51,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":42},"100511762","observational-study-on-functional-overlay-in-patients-with-movement-disorders-100511762","NCT05943652","Observational Study on \"Functional Overlay\" in Patients With Movement Disorders","Prevalence and Clinical Presentation of Functional Neurological Disorders in Patients With Movement Disorders - A Cross-sectional Study in the Movement Disorders Clinic of the Department of Neurology, Medical University of Graz","Inclusion Criteria:\n\n* Functional or non-functional movement disorder\n* 18 to 80 years\n\nExclusion Criteria:\n\n* Patient is not able to consent\n* Patient is not able to understand \u002F speak German fluently (questionnaires are available only in German)",{"count":242,"type":21},216,"The goal of this observational study is to learn about functional neurological disorders in patients with common non-functional movement disorders (\"functional overlay\"). The main questions it aims to answer are:\n\n* What is the frequency of functional neurological disorders in patients with non-functional movement disorders (functional overlay)?\n* What are the characteristics of functional neurological disorders in patients with non-functional movement disorders?\n\nParticipants will be examined clinically and electrophysiologically, the examinations consist of:\n\n* a neurological examination\n* neuropsychological testing\n* electrophysiological tremor diagnostic\n* questionnaires about psychological, biological and social risk factors\n\nResearchers will compare patients with functional motor disorders to patients wit non-functional movement disorders to see if they differ from each other regarding the functional symptoms.",[245,136,26,138],"Conversion Disorder",[247,248,249],"Accelerometry","Patient Health Questionnaire","Neuropsychology","2025-09-23",{"date":252,"type":34},"2025-09-29",{"date":254,"type":34},"2023-01-01",{"date":256,"type":21},"2026-06-30",{"name":258,"class":77},"Medical University of Graz",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":267,"conditions":268,"keywords":271,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":42},"100188855","stereotactic-radiosurgery-for-essential-tremor-and-parkinsonian-tremor-100188855","NCT01734122","Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor","Inclusion Criteria:\n\n* Must be certified by a neurologist as having essential tremor or Parkinsonian tremor that is insufficiently controlled by medication alone.\n* Preference to receive radiation treatment for tremor treatment, rather than surgical DBS implantation or surgical thalamotomy\n* At least 18 years old\n\nExclusion Criteria:\n\n* Contraindications to cranial radiation (such as prior radiation to the thalamus)\n* Inability to have a MRI of the brain\n* Prior surgical thalamotomy treatment (but contralateral deep brain stimulator \\[DBS\\] is permitted)\n* Estimated life expectancy less than 1 year",{"count":266,"type":21},60,"The purpose of this study is to determine the changes in quality of life and degree of tremor for patients with essential tremor or Parkinsonian tremor who are treated by stereotactic radiosurgery (SRS). This is a questionnaire-based study. Please see Detailed Description below for more information.",[26,137,136,269,270],"Radiosurgery","Quality of Life",[272,137,273,270,274],"Stereotactic Radiosurgery","Parkinsonian Tremor","Severity of Tremor","2025-09-05",{"date":277,"type":34},"2025-09-12",{"date":279,"type":34},"2013-02-21",{"date":281,"type":21},"2028-09",{"name":283,"class":77},"Vanderbilt University Medical Center",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":291,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":54,"phases":294,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":42},"100596709","phase-1-deep-brain-stimulation-of-the-deep-cerebellar-nuclei-for-refractory-tremor-100596709","NCT07049003","Deep Brain Stimulation of the Deep Cerebellar Nuclei for Refractory Tremor","rT DBS","Inclusion Criteria:\n\n* Age 21 years and older;\n* Ability to give informed consent;\n* Diagnosis of ET, cerebellar tremor, or MS-related tremor with a failed a prior intervention (VIM DBS or HIFU thalamotomy) or determined to not be suitable candidates for VIM DBS or HIFU thalamotomy because they have a cerebellar outflow or MS-related tremor.\n* Tremor history of at least three years;\n* Tremor that is refractory to medical management;\n* A score of ≥24 on the Mini Mental State Examination;\n* Inability to successfully perform ADLs without assistance or has lost interest in social, professional, or personal activities due to tremor\n\nExclusion Criteria:\n\n* Any other neurological condition that could reduce the safety of study participation including central nervous system vasculitis and intracranial malignancy\n* A condition that, in the opinion of the clinical investigator, would significantly increase the risk or interfere with study compliance, safety, or outcome;\n* A diagnosis of dementia;\n* Tremors due to other neurological conditions such as Parkinson's disease, dystonia, or other conditions not consistent with ET, cerebellar outflow tremor, or MS-related tremor.\n* Diagnosis of epilepsy;\n* Major active and untreated psychiatric illness that may interfere with study, such as psychotic disorders or severe personality disorders;\n* Untreated or inadequately treated depression defined by a score of 20 or greater on the Beck Depression Inventory-II at the time of enrollment;\n* At risk for suicide defined by a score greater or equal to 3 on the Columbia Suicide Severity Rating Scale (C-SSRS);\n* Pregnancy;\n* Unable to communicate with investigators or staff;\n* Surgical contraindications to DN DBS;\n* Contraindication to magnetic resonance (MRI) imaging, e.g., weight incompatible with scanner, implanted metallic devices or electrical devices (pacemaker, defibrillator, spinal cord stimulator, prior DBS) or intolerance to MRI contrast agent;\n* Enrolled in another device, biologic or pharmaceutical study within 30 days of consent in the current study, (i.e., patient cannot be enrolled if participation in another study was not completed at least 30 days prior to consent.);\n* Evidence of behavior(s) consistent with alcohol or substance abuse\u002Fdependence as defined by the criteria outlined in the DSM-V within the preceding six months;\n* Injection of botulinum toxins into the arm, neck or face within six months prior to baseline;","21 Years",{"count":293,"type":21},12,[295],"PHASE1","This objective of this study is to document the safety and feasibility of electrical stimulation of the deep cerebellar nuclei for refractory tremor using the Medtronic Percept RC Deep Brain Stimulation System. The population will consist of patients that have either failed a prior intervention (Vim DBS or HIFU thalamotomy) or determined to not be suitable candidates for Vim DBS or HIFU thalamotomy because they have a cerebellar outflow or MS-related tremor. Those patients with a previous intervention, must have a prior diagnosis of ET, cerebellar outflow tremor, or MS-related tremor. Subjects without a previous intervention must have a diagnosis of cerebellar outflow tremor or MS-related tremor.",[26,137],"2025-06-30",{"date":300,"type":34},"2025-07-03",{"date":302,"type":34},"2025-05-19",{"date":304,"type":21},"2028-12-31",{"name":306,"class":77},"The Cleveland Clinic",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":315,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":319,"conditions":320,"keywords":321,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":42},"100545186","tapping-test-and-the-archimedean-spiral-for-the-differential-diagnosis-of-tremor-machine-learning-approach-100545186","NCT06378619","Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach","Machine Learning Analysis Of The Tapping Test And The Archimedean Spiral For The Differential Diagnosis Of Essential Tremor And Parkinson's Disease.","MATSEP","Inclusion Criteria:\n\n* Possibility to collaborate in the necessary evaluations.\n* Follow-up in the specialized consultation of Movement Disorders at the Neurology Service of Hospital Sant Camil-Consorci Sanitari Alt Penedes i Garraf.\n* Legal capacity to provide informed consent.\n* Signature of informed consent for study inclusion, either by the participant themselves or by their legal representative.\n* Participant with criteria from Group 1 or 2:\n\nGroup 1:\n\n* Confirmed diagnosis of tremor due to Parkinson's disease, clinically established, based on the diagnostic criteria of the Movement Disorders Society, and additionally:\n* Tremor associated with bradykinesia of any duration.\n* Confirmatory clinical diagnosis of tremor due to Parkinson's disease (stages 1 to 2 of Hoehn and Yahr) by the neurologist responsible for the participant's follow-up.\n\nGroup 2:\n\n* Confirmed diagnosis of essential tremor, based on the criteria of the Movement Disorders Society, and additionally:\n* Positional tremor plus kinetic and\u002For resting tremor with follow-up in outpatient neurology consultations for at least 3 years without a change in diagnosis.\n* Absence of bradykinesia.\n\nExclusion Criteria:\n\n* Patients undergoing treatment with antipsychotics or antidepressants.\n* Patients with Parkinson's disease and dyskinesias.\n* Patients undergoing treatment with dopaminergic agonists or primidone.\n* Tremor of such severity that it prevents continuous tracing, at the investigator's discretion.\n* Cognitive or affective pathology that limits the ability to collaborate with the study procedures.\n* Participation in another clinical study involving an intervention, procedure, or visit frequency that is incompatible with the present study.\n* Participants diagnosed with any of the following conditions:\n\nAlcoholism of sufficient intensity to influence handwriting or cause neuropathy, at the investigator's discretion. Peripheral neuropathy of any cause. Dystonias. Previous stroke.","45 Years","79 Years",{"count":318,"type":21},110,"In clinical practice, it is sometimes difficult to establish whether a patient's tremor is due to Parkinson's disease or essential tremor. The distinction is crucial as the health implications differ significantly between the two conditions. Therefore, the present study aims to develop a diagnostic method based on machine learning techniques to help differentiate whether a patient's tremor is due to one condition or the other. To achieve this, 110 patients with tremor, correctly diagnosed with either Parkinson's disease or essential tremor, will participate. They will undergo two diagnostic tests (tapping test and Archimedean spiral) to capture data that can be processed using machine learning techniques.",[26,137,136],[26,137,136,322,323],"Diagnosis, Differential","Machine Learning","2025-06-23",{"date":326,"type":34},"2025-06-26",{"date":328,"type":34},"2024-07-15",{"date":330,"type":21},"2026-07",{"name":332,"class":77},"Consorci Sanitari de l'Alt Penedès i Garraf",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":54,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":348,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":42},"100569729","optimizing-vim-targeting-for-radiosurgery-in-severe-tremor-100569729","NCT06698029","Optimizing VIM Targeting for Radiosurgery in Severe Tremor","Optimisation du Ciblage du VIM Pour la Radiochirurgie Dans le Tremblement sévère","OptiRS","Inclusion Criteria:\n\n* Advanced, disabling, drug-resistant essential tremor\n* Patient selected as part of the multidisciplinary concertation meeting on abnormal movements\n* Patient aged 18 to 85\n* Brain MRI showing no anatomical abnormality contraindicating radiosurgical procedure\n* MATTIS ≥ 130\n* Subject affiliated to or benefiting from a social security scheme\n* Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Patients with a contraindication to brain MRI (pacemaker, intracerebral metal object, etc.)\n* Pregnant or breast-feeding women","85 Years",{"count":343,"type":21},40,[56],"Essential tremor is a common neurological disease, the most severe form of which combines postural and intention tremor, with significant physical, psychological and social repercussions. It is in these most severe forms that surgical lesioning of the ventro-intermediate nucleus of the thalamus (VIM) has been proposed. The VIM and its region of interest are almost impossible to identify directly on imaging (especially MRI), as it is part of the thalamus, which has the same intensity. To identify it, teams use average coordinates from stereotactic atlases (imprecise due to the high inter-individual variability of brain anatomy) or retrospective series of implanted patients. The hypothesis of the present trial is that the VIM-RS-LAT-1.0 algorithm developed by RebrAIn for radiosurgery will enable targeting that is at least as effective as conventional targeting. This is a single-center, controlled study, the primary endpoint of which will be assessed at one year, in a blinded, phase 3, comparative, non-inferiority, randomized study in two parallel groups of patients with severe tremor undergoing radiosurgery. In the control group, VIM will be targeted conventionally, and in the experimental group, VIM will be targeted by the RebrAIn algorithm (VIM-RS-LAT-1.0 model) of radiosurgery.",[26,347],"Laser Therapy","NOT_YET_RECRUITING","2024-11-18",{"date":351,"type":34},"2024-11-20",{"date":353,"type":21},"2025-01-01",{"date":355,"type":21},"2027-12-31",{"name":357,"class":77},"Assistance Publique Hopitaux De Marseille",{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":54,"phases":368,"briefSummary":370,"conditions":371,"keywords":376,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":385,"locationsCount":42},"100446143","phase-4-tacrolimus-associated-tremors-in-liver-transplantation-immediate-release-versus-extended-release-formulations-100446143","NCT05089604","Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations","Tacrolimus Associated Tremors in Liver Transplant Recipients: a Randomized Open Label Trial Comparing De Novo Extended-release Once Daily (LCP-TAC) and Twice Daily Immediate-release (IR-TAC) Tacrolimus Formulations","LCP-TAC","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Recipients of a first-time liver transplant\n3. eGFR more than 30 ml\u002Fmin on the day of tacrolimus initiation\n4. All patients who are eligible to initiate Tacrolimus within 7 days post-liver transplant\n5. Informed consent\n\nExclusion Criteria:\n\n1. Recipients of prior organ transplant\n2. Need for hemodialysis either prior or following liver transplantation\n3. Recipients of living donor liver or split deceased donor liver allografts\n4. Recipients of combined liver\u002Fkidney transplants\n5. Recipients receiving liver allografts from donors with HCV viremia (detected through nucleic acid testing or other means)\n6. Patients with a history of tremor prior to transplantation including essential tremors, Parkinson's or Parkinsonian syndromes\n7. Patients receiving concomitant medications known to induce tremors such as dopamine blocking agents\n8. Baseline TSH, T3, T4 indicating hyperthyroidism",{"count":367,"type":21},124,[369],"PHASE4","This is a randomized open label study in de novo liver transplant recipients that aims to compare the risk of tacrolimus induced tremors with once daily extended-release formulation, Envarsus, versus the twice daily immediate-release formulation. Both formulations of tacrolimus are currently approved for the prevention of rejection in liver transplant patients.",[372,373,374,26,375],"Liver Transplantation","Immunosuppression","Neurotoxicity","Tacrolimus",[377,375,373,26,378,364,374],"Liver Transplant","Envarsus","2023-12-27",{"date":381,"type":34},"2024-01-02",{"date":383,"type":34},"2023-01-09",{"date":74,"type":21},{"name":386,"class":77},"University of British Columbia"]